Vesicare · DIN 02277263 · 5 mg · tablet
Limited Use, Reason for Use code 290 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 290 required
Write on scriptReason for Use code 290 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 290
Reason for Use code 290
For patients with urinary frequency, urgency or urge incontinence who have:
Failed to respond to behavioral techniques AND an adequate trial of oxybutynin with gradual dose escalation has shown to be either ineffective or resulted in unacceptable side effects.
NOTE: If after a trial of 2 weeks patients continue to experience similar side effects and no greater efficacy than oxybutynin, continued therapy with this more costly agent should be reassessed.
Antimuscarinic agents should be used with caution in the elderly due to potentially serious adverse effects (e.g. confusion, psychosis, acute urinary retention, constipation). Antimuscarinic agents should be avoided in older adults with pre-existing cognitive impairment (e.g. dementia) and those who are already using other drugs with significant anticholinergic effects (e.g. tricyclic antidepressants) in order to avoid a high overall anticholinergic drug burden.
Coverage limit:
LU Authorization Period: Indefinite
1 brand, same coverage
Vesicare · DIN 02277263
Manufacturer: Astellas Pharma Canada Inc.; listing date 2011-12-15
Health Canada: Marketed since 2006-06-23 · brand VESICARE · ATC G04BD08 SOLIFENACIN · form Tablet · route Oral · ingredients SOLIFENACIN SUCCINATE 5 MG · company Astellas pharma canada inc · schedule Prescription
Ministry pays: $0.3041 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02277263)
Source record
DIN 02277263: Vesicare
Raw flags: sec12=Y, sec3=Y
Item: 920000638; group id 963; item number 2285; lccId 00218; manufacturer id ASE
Source form: Tab; strength: 5mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $1.6892; ministry $0.3041
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02277263
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=76292
Interchangeable products
Ach-Solifenacin Succinate · DIN 02439344 · $0.3041
Act Solifenacin · DIN 02422239 · $0.3041
Apo-Solifenacin · DIN 02423375 · $0.3041
Auro-Solifenacin · DIN 02446375 · $0.3041
Jamp Solifenacin Succinate · DIN 02428911 · $0.3041
Jamp-Solifenacin · DIN 02424339 · $0.3041
M-Solifenacin Succinate · DIN 02529696 · $0.3041
PMS-Solifenacin · DIN 02417723 · $0.3041
PRZ-Solifenacin · DIN 02493039 · $0.3041
Ran-Solifenacin · DIN 02437988 · $0.3041
Sandoz Solifenacin · DIN 02399032 · $0.3041
Solifenacin · DIN 02458241 · $0.3041
Solifenacin Succinate Tablets · DIN 02448335 · $0.3041
Teva-Solifenacin · DIN 02397900 · $0.3041
Shortage status: not checked (no credentials)